教育经历
2022.07-2024.06,中国科学院广州生物医药与健康研究院,博士后
2017.09-2022.06,中国科学院广州生物医药与健康研究院,药物化学,博士
2013.09-2017.06,华南农业大学,制药工程,学士
工作经历
2025.01-至今,中国科学院广州生物医药与健康研究院,副研究员
2024.07-2024.12,中国科学院广州生物医药与健康研究院,助理研究员
表观遗传调控靶标抗肿瘤靶向药物研究。
1. 国家自然科学基金青年项目,22307116,2024.01-2026.12,主持;
2、中国博士后科学基金面上项目,2023M733518,2023.03-2024.07,主持;
3、广州市基础研究计划基础与应用基础研究-青年博士“启航”项目,2025A04J4520,2025.01-2026.12,主持;
4、国家自然科学基金面上项目,82173745,2022.01-2025.12,参与;
5、呼吸疾病全国重点实验室自主项目,SKLRD-Z-202217,2022.01-2024.12,参与;
6、国家重点研发计划项目,2019YFE0123700,2020.12-2023.11,参与;
7、广州市基础研究计划基础与应用基础研究项目,202102080215,2021.04-2023.03,参与。
1、Junhua Li1, QingQing Hu1, Run Zhu1, Ruibo Dong, Hui Shen, Jiankang Hu, Cheng Zhang, Xiaohan Zhang, Tingting Xu, Qiuping Xiang, Yan Zhang, Bin Lin, Linxiang Zhao,* Xishan Wu,* Yong Xu*. Discovery of the First BRD4 Second Bromodomain (BD2)-Selective Inhibitors. Journal of Medicinal Chemistry 2024, 67, 21577-21616.
2、Junhua Li1, Cheng Zhang1, Hongrui Xu, Chao Wang, Ruibo Dong, Hui Shen, Xiaoxi Zhuang, Xiaoshan Chen, Qiu Li, Jibu Lu, Maofeng Zhang, Xishan Wu, Kerry M. Loomes, Yulai Zhou, Yan Zhang, Jinsong Liu, Yong Xu*. Structure-Based Discovery and Optimization of Furo[3,2-c]pyridin-4(5H)-one Derivatives as Potent and Second Bromodomain (BD2)-Selective Bromo and Extra Terminal Domain (BET) Inhibitors. Journal of Medicinal Chemistry 2022, 65, 5760-5799.
3、Junhua Li, Run Zhu, Xiaoxi Zhuang, Cheng Zhang, Hui Shen, Xishan Wu, Maofeng Zhang, Cen Huang, Qiuping Xiang, Linxiang Zhao, Yong Xu*, Yan Zhang*. Rational Design, Synthesis and Biological Evaluation of Benzo[d]isoxazole Derivatives as Potent BET Bivalent Inhibitors for Potential Treatment of Prostate Cancer. Bioorganic Chemistry 2023, 135, 106495.
4、Run Zhu1, Junhua Li1*, Ruibo Dong, Qingqing Hu, Zhiming Chen, Xiaoshan Chen, Zhixin Zhong, Qiuping Xiang, Cen Huang, Bin Lin, Xishan Wu, Yan Zhang, Linxiang Zhao*, Yong Xu*. Optimization of the Synthesis of BET BD2 Selective Inhibitor XY153. Chemistry & Biodiversity 2024, e202301584.
5、Qiu Li1, Benqiang Yao1, Shiting Zhao, Zhou Lu, Yan Zhang, Qiuping Xiang, Xishan Wu, Haonan Yu, Cheng Zhang, Junhua Li, Xiaoxi Zhuang, Donghai Wu, Yong Li*, and Yong Xu*. Discovery of a Highly Selective and H435R-Sensitive Thyroid Hormone Receptor β Agonist. Journal of Medicinal Chemistry 2022,65,7193-7211.
6、Hui Shen,Hongrui Xu,Weiqin Jin,Tianbang Wu,Jiankang Hu,Cheng Zhang,Zhixin Zhong,Junhua Li,Rui Mao,Sheng Zhang,Xiao Zhang,Xishan Wu,Jeff Smaill,Jinxin Xu,Yan Zhang*;Xu,Yong*. Discovery of a Potent and Selective GSPT1 Molecular Glue Degrader for the Treatment of Castration-resistant Prostate Cancer. Journal of Medicinal Chemistry 2024,68,1553-1571.